BR112023027312A2 - Imunocitocina - Google Patents

Imunocitocina

Info

Publication number
BR112023027312A2
BR112023027312A2 BR112023027312A BR112023027312A BR112023027312A2 BR 112023027312 A2 BR112023027312 A2 BR 112023027312A2 BR 112023027312 A BR112023027312 A BR 112023027312A BR 112023027312 A BR112023027312 A BR 112023027312A BR 112023027312 A2 BR112023027312 A2 BR 112023027312A2
Authority
BR
Brazil
Prior art keywords
immunocytocin
immunocytokines
immunocytokine
superagonists
vectors
Prior art date
Application number
BR112023027312A
Other languages
English (en)
Portuguese (pt)
Inventor
David Béchard
Eva Nedvedová
Luc Michel De Martynoff Guy
Irena Adkins
Iva Valentová
Kyrych Sadilkova Lenka
Lorenz Waldmeier
Lukas Bammert
Renzo Beerli Roger
Simona Hosková
Sárka Pechoucková
Ulrich Moebius
Zuzana Antosová
Original Assignee
Cytune Pharma
Sotio Biotech A S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytune Pharma, Sotio Biotech A S filed Critical Cytune Pharma
Publication of BR112023027312A2 publication Critical patent/BR112023027312A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112023027312A 2021-06-23 2022-06-23 Imunocitocina BR112023027312A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21181271 2021-06-23
EP22163748 2022-03-23
PCT/EP2022/067236 WO2022268983A2 (en) 2021-06-23 2022-06-23 Interleukin-15 based immunocytokines

Publications (1)

Publication Number Publication Date
BR112023027312A2 true BR112023027312A2 (pt) 2024-03-12

Family

ID=82361370

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023027312A BR112023027312A2 (pt) 2021-06-23 2022-06-23 Imunocitocina

Country Status (10)

Country Link
US (1) US20240294594A1 (https=)
EP (1) EP4359428A2 (https=)
JP (1) JP2024524891A (https=)
KR (1) KR20240024242A (https=)
AU (1) AU2022296794A1 (https=)
BR (1) BR112023027312A2 (https=)
CA (1) CA3221886A1 (https=)
IL (1) IL309533A (https=)
MX (1) MX2023015444A (https=)
WO (1) WO2022268983A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016002614B8 (pt) 2013-08-08 2023-11-07 Hopitaux Paris Assist Publique Imunocitoquina e composição farmacêutica
EP4069738A1 (en) * 2019-12-06 2022-10-12 SOTIO Biotech a.s. Humanized cldn18.2 antibodies
WO2025177263A1 (en) * 2024-02-25 2025-08-28 Biohaven Therapeutics Ltd. Myostatin-binding proteins

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI259837B (en) 1998-05-11 2006-08-11 Eidgenossische Tech Hochscule Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
US20100082438A1 (en) 2008-10-01 2010-04-01 Ronnie Jack Garmon Methods and systems for customer performance scoring
AU2009336800A1 (en) 2009-01-07 2011-07-21 Philogen S.P.A. Cancer treatment
CA2902739C (en) * 2013-03-15 2022-11-22 Xencor, Inc. Heterodimeric proteins
EP2988784A1 (en) 2013-04-25 2016-03-02 Philogen S.p.A. Antibody-drug conjugates
AU2016365114A1 (en) 2015-11-30 2018-05-17 Abbvie Biotherapeutics Inc. Anti-huLRRC15 antibody drug conjugates and methods for their use
CN110214147A (zh) * 2016-10-14 2019-09-06 Xencor股份有限公司 IL15/IL15Rα异源二聚体FC-融合蛋白
RU2761377C2 (ru) 2017-04-03 2021-12-07 Ф. Хоффманн-Ля Рош Аг Иммуноконъюгаты антитела к pd-1 с мутантом il-2 или с il-15
JP2021516045A (ja) 2018-02-28 2021-07-01 ファイザー・インク Ｉｌ−１５バリアントおよびその使用
JP2021514625A (ja) * 2018-03-01 2021-06-17 グリコトープ ゲーエムベーハー 抗ｍｕｃ１抗体およびｉｌ−１５を含む融合タンパク質構築物
CA3097625A1 (en) * 2018-04-18 2019-10-24 Xencor, Inc. Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof
AU2019359475A1 (en) * 2018-10-12 2021-05-20 Xencor, Inc. PD-1 targeted IL-15/IL-15Ralpha Fc fusion proteins and uses in combination therapies thereof
US11738050B2 (en) 2019-02-01 2023-08-29 Regents Of The University Of Minnesota Compounds binding to fibroblast activation protein alpha
WO2021057826A1 (zh) * 2019-09-25 2021-04-01 北京志道生物科技有限公司 一种重组白介素-15类似物

Also Published As

Publication number Publication date
CA3221886A1 (en) 2022-12-29
EP4359428A2 (en) 2024-05-01
US20240294594A1 (en) 2024-09-05
KR20240024242A (ko) 2024-02-23
JP2024524891A (ja) 2024-07-09
WO2022268983A2 (en) 2022-12-29
AU2022296794A1 (en) 2023-12-14
WO2022268983A3 (en) 2023-04-06
IL309533A (en) 2024-02-01
MX2023015444A (es) 2024-04-29

Similar Documents

Publication Publication Date Title
BR112023027312A2 (pt) Imunocitocina
MY193354A (en) Anti-vegf protein compositions and methods for producing the same
BR112021026376A2 (pt) Proteínas de fusão flt3l-fc e métodos de uso
DK202300015Y9 (da) Ikke-animalsk baserede proteinkilder med funktionelle egenskaber
MX2022008602A (es) Polinucleotidos que codifican interleucina-12 (il 12) y usos de los mismos.
MX2021007070A (es) Mutantes de proteina f de rsv.
PH12020552181A1 (en) Constructs targeting prostate-specific membrane antigen (psma) and uses thereof
CY1111819T1 (el) Αντισωμα εναντι epcam και χρησεις αυτου
WO2019209885A3 (en) Enzyme engineering to alter the functional repertoire of cannabinoid synthases
MX2020006635A (es) Proteína de fusión enzimática terapéutica que tiene una nueva estructura y uso de la misma.
EA201690333A1 (ru) МОДУЛОКИНЫ НА ОСНОВЕ ДОМЕНА SUSHI IL-15 И IL-15Rα
CY1110868T1 (el) Ελαχιστη αλληλουχια dna που δρα ως μονωτης της χρωματινης και η χρηση της στην πρωτεϊνικη εκφραση
BR112023024837A2 (pt) Anticorpos anti-ccr8
AR115695A1 (es) Moléculas proteicas multifuncionales que comprenden decorina y uso de estas
CY1114526T1 (el) Κατασταλτικες πρωτεϊνες μιας πρωτεασης (protease) και χρησεις αυτων
JOP20230265A1 (ar) تركيبات جسم مضاد ضد tslp واستخداماتها
CO2024007212A2 (es) Péptidos inmunogénicos magea1, proteínas de unión que reconocen péptidos inmunogénicos magea1, y usos de estos
MX2023007326A (es) Moleculas de fusion inmunomoduladoras localizadas por colageno lineales bifuncionales y metodos de las mismas.
MX2025005092A (es) Anticuerpo anti-trem2 y usos del mismo
CO2024007674A2 (es) Anticuerpo anti-trem2 y usos del mismo
WO2022051437A3 (en) Methods to stimulate hla-agnostic immune responses to proteins using nucleated cells
MX2024008163A (es) Anticuerpos de afinidad alta de dominio unico y metodos de uso de estos.
MX2020002283A (es) Vacuna recombinante contra la enteropatia proliferativa en animales.
MX2023011919A (es) Construcciones de proteinas de union a antigenos y anticuerpos y usos de estos.
WO2021158982A3 (en) Targeted translation of rna with crispr-cas13 to enhance protein synthesis